He received a second course of prednisone, which resulted in amelioration of clinical manifestations.
At 9 months after the second BMT, the boy suddenly presented pallor, vomiting and tachycardia. The laboratory data showed: a hemoglobin level of 4 g/dl, increased reticulocytes and decreased haptoglobin. The serologic data at diagnosis and during his outcome are shown in Table 1 . In serum, an antibody reacting at 371C with IgG reagent (detected using the pre-warmed technique) and a cold antibody reacting with a thermal amplitude between 221C and 261C were found. Neither of them could be identified. As the child was receiving prednisone for skin chronic GVHD, the steroid dose was increased to 2 mg/kg/ day, cyclosporin A was reinitiated and IVIG (2 g/kg total dose) was also administered, but the patient still showed no response. At 7 weeks after the diagnosis of AIHA, he received rituximab at 375 mg/m 2 /dose intravenously once weekly for four doses, after informed parental consent was obtained. A week after the first dose of rituximab, hemoglobin level rose from 4.7 to 6.5 g/dl and B lymphocytes were no longer detectable in peripheral blood. IVIG (400 mg/kg every 3 weeks) administration was maintained due to the fact IgG levels were below the normal range. After the fourth dose of rituximab, hemoglobin level was 10.8 g/dl and steroids were tapered slowly. After 5 months, a progressive increase of B lymphocytes from the donor, along with a persistent normalization of the hemoglobin levels, were observed (data shown in Figure 1 ). IVIG supplementation was discontinued 28 months after the second transplant, and 5 months later antibody response to tetanus toxoid was detected.
At 1 month after the last dose of rituximab, the patient had a pneumopathy with a positive bronchoalveolar lavage culture for Pseudomonas aeruginosa, which required oxygen and resolved after parenteral antibiotics. Yes  4+  4+  3+  4+  4+  3+  1+  -2+  10  Yes  4+  4+  3+  3+  -1+  2+  11  Yes  4+  4+  2+  2+  4+  1+  1+  -3+  12  Yes  4+  4+  1+  2+  4+  ---3+  12  No  4+  4+  -2+  4+  ---3+  14  No  4+  4+  -2+  2+  ---2+  18  No  3+  3+  1+  2+  3+  ---2+  21  No  4+  3+  1+ weak  2+  4+  ---2+  23  No  4+  4+  -2+  3+  ---2+  29  No  4+  3+  -1+  4+  ---3+  37  No  3+  3+  --4+  ---2+  43  No  3+  3+  --4+  ---2+ At 20 months after the transplant, the boy presented peripherally enlarging white patches, with somewhat hyperpigmented margins around the mouth, dorsum of hands and feet. The skin biopsy of two lesions was compatible with vitiligo. Cutaneous lesions became more extended, so a combination of oral psoralen and UVA exposure was used. After 16 exposures (cumulative dose of approximately 51 joules/cm 2 ) no improvement was noted and PUVA therapy was discontinued.
Autoimmune hemolytic anemia (AIHA) with a frequency of 5% has been reported in children with SCID who have undergone TCD BMT. 2 The outcome of severe childhood AIHA following HSCT with ineffective response to conventional immunosuppressive therapy is usually dismal.
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T-cell precursors may undergo aberrant thymic education after HSCT, contributing to both the immunodeficiency and autoimmunity that characterise chronic GVHD and autoimmune diseases post-HSCT. 6 Rituximab results in prolonged and severe B-cell depletion.
3-5 This antibody is increasingly being used for the treatment of AIHA refractory to conventional therapy.
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A good response to rituximab has been described in three children with AIHA following HSCT performed for the treatment of mucopolysaccharidosis.
So far, a better response to rituximab could be achieved in patients with cold-agglutinin disease, as compared with warm-autoantibody AIHA. 3, 4 At present, this 5-year-old boy is in good clinical condition and free of infectious events. Although his hemoglobin level is within normal values and the cold antibody has been undetectable for the last 10 months, the DAT, the IAT and the warm autoantibody have been repeatedly positive with a slow progressive decrease in strength of reaction (data summarized in Table 1) . A normal and a progressive reconstitution of T-and B-cell functions have also been found, respectively.
To our knowledge, this is the first reported case of a successful treatment of severe AIHA with rituximab in a child with SCID following TCD BMT. The kinetics and quality of the development of immune reconstitution have been similar to the data shown in other pediatric patients whose prospects of survival are related to long-term immune reconstitution. 
